Insulin resistance and cardiovascular risk factors in women with PCOS who have normal glucose tolerance test

References

• Slowey MJ. Polycystic ovary syndrome: new perspective on an old problem. South Med J 2001;94:190–196.
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078–3082.
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119–125.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006;20:193–205.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2031–2036.
   PubMed Web of Science ®Google Scholar
• Korhonen S, Hippeläinen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001;184:289–296.
   PubMed Web of Science ®Google Scholar
• Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997;17:695–701.
   PubMed Web of Science ®Google Scholar
• Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002;8:231–241.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229–232.
   PubMedGoogle Scholar
• Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 2003;52:908–915.
   PubMed Web of Science ®Google Scholar
• Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453–2455.
   PubMed Web of Science ®Google Scholar
• Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril 2006;86:20–21.
   PubMed Web of Science ®Google Scholar
• Jadhav UM, Kadam NN. Carotid intima-media thickness as an independent predictor of coronary artery disease. Indian Heart J 2001;53:458–462.
   PubMedGoogle Scholar
• Mukherjee D, Yadav JS. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 2002;144:753–759.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S, Labella D, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9:505–510.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
   PubMed Web of Science ®Google Scholar
• Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224–9; discussion 1229.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588–4593.
   PubMed Web of Science ®Google Scholar
• Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–789.
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454–1460.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–369.
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160–2165.
   PubMed Web of Science ®Google Scholar
• Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163–170.
   PubMed Web of Science ®Google Scholar
• Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR 3rd, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:E16–E22.
   PubMedGoogle Scholar
• O’Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002;90:18L–21L.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Nieto FJ, Szklo M, Barnes R, Sharrett AR, Ko WJ. Risk factors for popliteal and carotid wall thicknesses in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1999;150:1055–1067.
   PubMed Web of Science ®Google Scholar
• Ercan EA, Ertek S, Is G, Caglar O, Oztas E, Cicero AF, Alhan A, et al. Factors associated with increased carotid intima-media thickness and being nondipper in nonobese and normotensive young patients affected by PCOS. Angiology 2011;62:543–548.
   PubMed Web of Science ®Google Scholar
• Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 1999;72:990–995.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951–953.
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, De Feo P, Orio F Jr. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3128–3135.
   PubMed Web of Science ®Google Scholar